"This is disappointing, to say the least," said Rick Kingston , PharmD, president of regulatory and scientific affairs at SafetyCall International in Minneapolis, MN, and professor of pharmacy at the University of Minnesota College of Pharmacy.
"Notwithstanding major design flaws in the study in identifying an appropriate compound to represent available ginkgo in the market," continued Dr. Kingston, "even the reviewers voiced adamant proclamations that the results in this animal research were not intended for direct extrapolation to humans. For this oversight to not be reconciled by the NTP review group is disconcerting, especially since misinterpretation of the results by well-intentioned, but scientifically unsophisticated media outlets, and possibly even consumer groups, should have been an expected outcome." Dr. Kingston also was a co-author of the public comments letter from ABC to NTP.
The ABC comments sent to NTP as part of the public comment process also called attention to other anomalies and/or problems with the NTP ginkgo studies as noted in the draft report. These include concerns that the Shanghai ginkgo extract used in the NTP study was from several different production batches, and that the ginkgo extract material used in the study was not analyzed for the presence of potential contaminants.
1. National Toxicology Program. NTP Technical Report on the Toxicology and Carcinogenesis Studies on Ginkgo Biloba Extract (CAS NO. 90045-36-6)
IN F344/N Rats and B6C3F1/N Mice. (Gavage Studies). March 2013. Available at: http://ntp.niehs.nih.gov/ntp/htdocs/LT_rpt
|SOURCE American Botanical Council|
Copyright©2012 PR Newswire.
All rights reserved